Total Quarterly Revenue of $4 million, up 9% year-over-year.Record Backlog of $54.9 million.Gross Margin of 42%.Cost-Cutting ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

VICTORIA, BC, Nov. 12, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company developing precision drug ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

NASA’s Coronal Diagnostic Experiment (CODEX) is set to launch to the International Space Station to explore new details about ...

On the right, you see the change in plasma kallikrein through the ... consistent with prior Phase 1 results. In our view, these results speak directly to the strong potential of 2002 to reset ...

The FDA has lifted clinical holds on trials of zevor-cel, satri-cel, and CT071, and trials will now resume in the US.

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

It's good news for aurora chasers as peak auroral activity occurs a few years after solar maximum, according to Brekke. This ...